JP2017524742A5 - - Google Patents

Download PDF

Info

Publication number
JP2017524742A5
JP2017524742A5 JP2017528754A JP2017528754A JP2017524742A5 JP 2017524742 A5 JP2017524742 A5 JP 2017524742A5 JP 2017528754 A JP2017528754 A JP 2017528754A JP 2017528754 A JP2017528754 A JP 2017528754A JP 2017524742 A5 JP2017524742 A5 JP 2017524742A5
Authority
JP
Japan
Prior art keywords
formula
compound
acid
alkyl
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017528754A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524742A (ja
JP6670310B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/NL2015/050555 external-priority patent/WO2016024858A1/en
Publication of JP2017524742A publication Critical patent/JP2017524742A/ja
Publication of JP2017524742A5 publication Critical patent/JP2017524742A5/ja
Application granted granted Critical
Publication of JP6670310B2 publication Critical patent/JP6670310B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017528754A 2014-08-12 2015-07-29 テトラヒドロキノリン誘導体の調製のための合成中間体の調製方法 Active JP6670310B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2014050556 2014-08-12
NLPCT/NL2014/050556 2014-08-12
PCT/NL2015/050555 WO2016024858A1 (en) 2014-08-12 2015-07-29 Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives

Publications (3)

Publication Number Publication Date
JP2017524742A JP2017524742A (ja) 2017-08-31
JP2017524742A5 true JP2017524742A5 (enExample) 2018-09-06
JP6670310B2 JP6670310B2 (ja) 2020-03-18

Family

ID=51429345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017528754A Active JP6670310B2 (ja) 2014-08-12 2015-07-29 テトラヒドロキノリン誘導体の調製のための合成中間体の調製方法

Country Status (28)

Country Link
US (1) US10112904B2 (enExample)
EP (2) EP3180314B1 (enExample)
JP (1) JP6670310B2 (enExample)
KR (1) KR102572626B1 (enExample)
CN (1) CN107108558B (enExample)
AR (1) AR101509A1 (enExample)
AU (1) AU2015302407B2 (enExample)
BR (1) BR112017002873B1 (enExample)
CA (1) CA2958040C (enExample)
CL (1) CL2017000367A1 (enExample)
CY (1) CY1125574T1 (enExample)
DK (1) DK3180314T3 (enExample)
EA (1) EA034357B1 (enExample)
ES (1) ES2926775T3 (enExample)
HR (1) HRP20221061T1 (enExample)
HU (1) HUE059947T2 (enExample)
IL (1) IL250525B (enExample)
LT (1) LT3180314T (enExample)
MA (1) MA40378B1 (enExample)
MX (1) MX367908B (enExample)
PL (1) PL3180314T3 (enExample)
PT (1) PT3180314T (enExample)
RS (1) RS63575B1 (enExample)
SG (1) SG11201701077XA (enExample)
SI (1) SI3180314T1 (enExample)
SM (1) SMT202200385T1 (enExample)
TW (1) TWI691490B (enExample)
WO (1) WO2016024858A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4125911B1 (en) 2021-03-05 2024-04-24 NewAmsterdam Pharma B.V. Obicetrapib for treatment of dementias
MX2024001170A (es) 2021-07-26 2024-05-14 Newamsterdam Pharma B V Tratamiento de personas hiporreactivas a his.
IL314031A (en) 2021-12-30 2024-09-01 Newamsterdam Pharma B V Obicetrapib and sglt2 inhibitor combination
PE20251749A1 (es) 2022-07-05 2025-07-09 Newamsterdam Pharma B V Sales de obicetrapib y procesos para su fabricacion y productos intermedios de estos
TW202416994A (zh) 2022-08-22 2024-05-01 荷蘭商新阿姆斯特丹製藥公司 固定劑量醫藥組合物及其用途
EP4661865A1 (en) 2023-02-07 2025-12-17 NewAmsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions
WO2025059594A1 (en) 2023-09-15 2025-03-20 Newamsterdam Pharma B.V. METHODS FOR TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH)
WO2025093129A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025093436A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025146262A1 (en) 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Obicetrapib for use in the treatment of hemoglobinopathies
WO2025146415A1 (en) 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Improvement in atherosclerotic plaque characteristics with obicetrapib
WO2026062050A1 (en) 2024-09-17 2026-03-26 Newamsterdam Pharma B.V. Obicetrapib for use in methods for treating a subject having heterozygous familial hypercholesterolemia (hefh) and/or atherosclerotic cardiovascular disease (ascvd)
WO2026063944A1 (en) 2024-09-21 2026-03-26 Newamsterdam Pharma B.V. Obicetrapib for the treatment of dementias
WO2026062049A1 (en) 2024-09-21 2026-03-26 Newamsterdam Pharma B.V., Obicetrapib for the treatment of dementias
WO2026087915A1 (en) 2024-10-25 2026-04-30 Newamsterdam Pharma B.V. Treatment and prevention of sepsis or other dysregulated inflammatory responses using cetp inhibitor obicetrapib

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
ES2256461T3 (es) * 2001-04-30 2006-07-16 Pfizer Products Inc. Compuestos utiles como intermediarios de derivados de 4-aminoquinolina.
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
CN101466679A (zh) * 2006-03-30 2009-06-24 田边三菱制药株式会社 制备四氢喹啉衍生物的方法
TW200808731A (en) * 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives

Similar Documents

Publication Publication Date Title
JP2018529687A5 (enExample)
HRP20221061T1 (hr) Postupak za pripremu sintetičkih intermedijera za pripremu tetrahidrokinolinskih derivata
JP2019048806A5 (enExample)
RU2015103694A (ru) Способы синтеза спиро-оксиндольных соединений
JP2018502909A5 (enExample)
JP2012515142A5 (enExample)
JP2015063536A5 (enExample)
JP2013032389A5 (enExample)
JP2014500861A5 (enExample)
RU2016135762A (ru) Способ получения (r)-1,1,3-триметил-4-аминоиндана
JP2021503464A5 (ja) レチノイドx受容体特異的なレチノイドの調製のための合成方法
CN109311892A (zh) 手性吡咯并嘧啶化合物的制备方法
CN111233829A (zh) 一种具有光学活性的尼古丁的制备方法
JP2014507414A5 (enExample)
JP2014528463A5 (enExample)
JP5451870B2 (ja) 光学的に純粋なアミノ酸を得る方法
JP2016516744A5 (enExample)
US10370329B2 (en) Process for the enantiomeric resolution of apremilast intermediates
JP2017533926A5 (enExample)
TWI455933B (zh) 貝他斯汀或其苯磺酸鹽之製法及其使用之中間體
JP2020502077A5 (enExample)
JP2017516808A5 (enExample)
JP2017509581A5 (enExample)
JP6228210B2 (ja) フルボキサミン遊離塩基の精製方法およびそれを用いた高純度フルボキサミンマレイン酸塩の製造方法
JP2005247850A5 (enExample)